{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-027734","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.318950+00:00","generated_at":"2026-05-26T03:39:57.345053+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alector Q4 net loss narrows to $2.1M; latozinemab Phase 3 data expected Q4 2025","bullets":["Q4 2024 net loss $2.1M ($0.02 loss per share) vs $41.4M loss ($0.49 loss) in Q4 2023, revenue $54.2M vs $15.2M.","Cash, cash equivalents and investments $413.4M, expected to fund operations through 2026.","Topline data from pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN anticipated by Q4 2025.","Enrollment in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer's expected to complete by mid-2025.","2025 guidance: collaboration revenue $5-15M, R&D expense $175-185M, G&A $55-65M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-027734","json":"https://secwatch.observer/filing/0000950170-25-027734.json","markdown":"https://secwatch.observer/filing/0000950170-25-027734.md","text":"https://secwatch.observer/filing/0000950170-25-027734.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017025027734/0000950170-25-027734-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017025027734/alec-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:39:57.345053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}